This issue is particularly important given the ongoing clinical trials investigating the efficacy of several SHP2 inhibitors either as monotherapies or in combination with molecularly targeted drugs or immune checkpoint inhibitors for human cancers, including NSCLC [121]. The gene discussed is PTPN11; the disease is cancer.